WBA241018P9500
- 0.86
- +0.01+1.18%
Walgreens Boots Alliance Newsroom
Morgan Stanley Maintains Walgreens Boots Alliance(WBA.US) With Sell Rating, Cuts Target Price to $7
A Quick Look at Today's Ratings for Walgreens Boots Alliance(WBA.US), With a Forecast Between $7 to $16
Walgreens Boots Alliance Analyst Ratings
Challenging Retail Environment and Declining Sales Justify Sell Rating for Walgreens Boots Alliance
Walgreens Boots Alliance: Buy Rating Affirmed Despite Adjusted EPS Estimates, With Positive Outlook on Store Optimization and PBM Negotiations
Walgreens Boots Alliance: Hold Rating Amidst Uncertainty and Market Pressures
Barclays Maintains Walgreens Boots Alliance(WBA.US) With Sell Rating, Maintains Target Price $7
Walgreens Boots Alliance Analyst Ratings
Truist Financial Maintains Walgreens Boots Alliance(WBA.US) With Hold Rating, Cuts Target Price to $10
Barclays Maintains Walgreens Boots Alliance(WBA.US) With Sell Rating, Maintains Target Price $7
Walgreens Boots Alliance: Liquidity Concerns Sustain Sell Rating
Walgreens Boots Alliance Is Maintained at Buy by TD Cowen
Walgreens Boots Alliance Analyst Ratings
TD Cowen Maintains Walgreens Boots Alliance(WBA.US) With Buy Rating, Cuts Target Price to $16
TD Cowen Cuts Price Target on Walgreens Boots Alliance to $16 From $22
Analysts Offer Insights on Healthcare Companies: Walgreens Boots Alliance (WBA), Belite Bio, Inc. ADR (BLTE) and Protagonist Therapeutics (PTGX)
Barclays Maintains Walgreens Boots Alliance(WBA.US) With Sell Rating, Maintains Target Price $7
BofA Securities Maintains Walgreens Boots Alliance(WBA.US) With Sell Rating, Cuts Target Price to $7.5
Walgreens Boots Alliance: Hold Rating Maintained Amidst Ongoing Headwinds and Financial Challenges
Walgreens Boots Alliance Is Maintained at Overweight by JP Morgan